Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1983 2
1985 1
1986 2
1989 2
1990 1
1992 1
1994 2
1995 5
1996 6
1997 3
1998 2
1999 2
2000 2
2001 8
2002 5
2003 4
2004 2
2005 3
2006 2
2007 4
2008 4
2009 1
2010 5
2011 6
2012 4
2013 5
2014 8
2015 5
2016 5
2017 8
2018 5
2019 7
2020 13
2021 3
2022 11
2023 8
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

152 results

Results by year

Filters applied: . Clear all
Page 1
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Komarnicki M, Suzuki K, Plesner T, Yoon SS, Ben Yehuda D, Richardson PG, Goldschmidt H, Reece D, Lisby S, Khokhar NZ, O'Rourke L, Chiu C, Qin X, Guckert M, Ahmadi T, Moreau P; POLLUX Investigators. Dimopoulos MA, et al. N Engl J Med. 2016 Oct 6;375(14):1319-1331. doi: 10.1056/NEJMoa1607751. N Engl J Med. 2016. PMID: 27705267 Free article. Clinical Trial.
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, Lindsay J, Weisel K, White D, Facon T, San Miguel J, Sunami K, O'Gorman P, Sonneveld P, Robak P, Semochkin S, Schey S, Yu X, Doerr T, Bensmaine A, Biyukov T, Peluso T, Zaki M, Anderson K, Dimopoulos M; OPTIMISMM trial investigators. Richardson PG, et al. Lancet Oncol. 2019 Jun;20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4. Epub 2019 May 13. Lancet Oncol. 2019. PMID: 31097405 Clinical Trial.
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Kaplan P, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Chiu C, Wang J, Carson R, Crist W, Deraedt W, Nguyen H, Qi M, San-Miguel J; ALCYONE Trial Investigators. Mateos MV, et al. N Engl J Med. 2018 Feb 8;378(6):518-528. doi: 10.1056/NEJMoa1714678. Epub 2017 Dec 12. N Engl J Med. 2018. PMID: 29231133 Free article. Clinical Trial.
Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations.
Pollyea DA, DiNardo CD, Arellano ML, Pigneux A, Fiedler W, Konopleva M, Rizzieri DA, Smith BD, Shinagawa A, Lemoli RM, Dail M, Duan Y, Chyla B, Potluri J, Miller CL, Kantarjian HM. Pollyea DA, et al. Among authors: shinagawa a. Clin Cancer Res. 2022 Jul 1;28(13):2753-2761. doi: 10.1158/1078-0432.CCR-21-3467. Clin Cancer Res. 2022. PMID: 35046058 Free PMC article.
Collection, mapping, and annotation of over 28,000 cDNA clones from japonica rice.
Rice Full-Length cDNA Consortium; National Institute of Agrobiological Sciences Rice Full-Length cDNA Project Team; Kikuchi S, Satoh K, Nagata T, Kawagashira N, Doi K, Kishimoto N, Yazaki J, Ishikawa M, Yamada H, Ooka H, Hotta I, Kojima K, Namiki T, Ohneda E, Yahagi W, Suzuki K, Li CJ, Ohtsuki K, Shishiki T; Foundation of Advancement of International Science Genome Sequencing & Analysis Group; Otomo Y, Murakami K, Iida Y, Sugano S, Fujimura T, Suzuki Y, Tsunoda Y, Kurosaki T, Kodama T, Masuda H, Kobayashi M, Xie Q, Lu M, Narikawa R, Sugiyama A, Mizuno K, Yokomizo S, Niikura J, Ikeda R, Ishibiki J, Kawamata M, Yoshimura A, Miura J, Kusumegi T, Oka M, Ryu R, Ueda M, Matsubara K; RIKEN; Kawai J, Carninci P, Adachi J, Aizawa K, Arakawa T, Fukuda S, Hara A, Hashizume W, Hayatsu N, Imotani K, Ishii Y, Itoh M, Kagawa I, Kondo S, Konno H, Miyazaki A, Osato N, Ota Y, Saito R, Sasaki D, Sato K, Shibata K, Shinagawa A, Shiraki T, Yoshino M, Hayashizaki Y, Yasunishi A. Rice Full-Length cDNA Consortium, et al. Among authors: shinagawa a. Science. 2003 Jul 18;301(5631):376-9. doi: 10.1126/science.1081288. Science. 2003. PMID: 12869764
Ixazomib-induced Sweet's syndrome.
Suyama T, Ito S, Shinagawa A. Suyama T, et al. Among authors: shinagawa a. Int J Hematol. 2020 Feb;111(2):161-162. doi: 10.1007/s12185-019-02797-6. Epub 2019 Dec 11. Int J Hematol. 2020. PMID: 31828594 No abstract available.
Identification of activating enzymes of a novel FBPase inhibitor prodrug, CS-917.
Kubota K, Inaba S, Nakano R, Watanabe M, Sakurai H, Fukushima Y, Ichikawa K, Takahashi T, Izumi T, Shinagawa A. Kubota K, et al. Among authors: shinagawa a. Pharmacol Res Perspect. 2015 Jun;3(3):e00138. doi: 10.1002/prp2.138. Epub 2015 May 4. Pharmacol Res Perspect. 2015. PMID: 26171222 Free PMC article.
152 results